Grace Kim - Cyclacel Pharmaceuticals Investor Executive
| CYCC Stock | USD 0.41 0.06 17.14% |
Executive
Grace Kim is Investor Executive of Cyclacel Pharmaceuticals
| Address | 200 Connell Drive, Berkeley Heights, NJ, United States, 07922 |
| Phone | 908 517 7330 |
| Web | https://www.cyclacel.com |
Cyclacel Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.0253) % which means that it has lost $1.0253 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7069) %, meaning that it created substantial loss on money invested by shareholders. Cyclacel Pharmaceuticals' management efficiency ratios could be used to measure how well Cyclacel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.43. The current year's Return On Capital Employed is expected to grow to -37.55. At present, Cyclacel Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 4.3 M, whereas Total Assets are forecasted to decline to about 8.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Garret Bonney | Ovid Therapeutics | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Meg Alexander | Ovid Therapeutics | N/A | |
| Steven CPA | NextCure | 61 | |
| Alexander Constan | Ikena Oncology | N/A | |
| Wendy CPA | Akari Therapeutics PLC | 57 | |
| Julia Tsai | Ovid Therapeutics | 49 | |
| Lora Pike | Ovid Therapeutics | N/A | |
| Lindsay Young | Tempest Therapeutics | N/A | |
| Sourav Kundu | NextCure | 63 | |
| Udayan MD | NextCure | N/A | |
| MD III | Akari Therapeutics PLC | 71 | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| BethAnne Lang | Akari Therapeutics PLC | N/A | |
| Stacy Rollinger | NextCure | N/A | |
| Daron Evans | Rezolute | 50 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| MS MBA | Rezolute | 50 | |
| Erin OBoyle | Rezolute | N/A | |
Management Performance
| Return On Equity | -5.71 | ||||
| Return On Asset | -1.03 |
Cyclacel Pharmaceuticals Leadership Team
Elected by the shareholders, the Cyclacel Pharmaceuticals' board of directors comprises two types of representatives: Cyclacel Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyclacel. The board's role is to monitor Cyclacel Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cyclacel Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyclacel Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gill Christie, Director Resources | ||
| Mark MD, Senior Officer | ||
| Spiro Rombotis, CEO and President and Executive Director | ||
| Robert Westwood, Head Devel | ||
| Brian MD, Interim Director | ||
| Paul McBarron, COO, CFO, Principal Accounting Officer, Executive VP of Fin. and Admin., Secretary and Executive Director | ||
| Grace Kim, Investor Executive |
Cyclacel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyclacel Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.71 | ||||
| Return On Asset | -1.03 | ||||
| Operating Margin | (911.00) % | ||||
| Current Valuation | (435.68 K) | ||||
| Shares Outstanding | 6.29 M | ||||
| Shares Owned By Insiders | 4.81 % | ||||
| Shares Owned By Institutions | 18.02 % | ||||
| Number Of Shares Shorted | 672.05 K | ||||
| Price To Earning | (0.40) X | ||||
| Price To Book | 2.02 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (27.40) | Revenue Per Share 0.044 | Quarterly Revenue Growth (0.99) | Return On Assets (1.03) | Return On Equity (5.71) |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.